Drug intelligence / Profile preview

VPM4001

Development stage: Unknown
Lead developer: Vakzine Projekt Management
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

VPM4001 is an allogeneic therapeutic cancer vaccine developed for the treatment of prostate carcinoma. It consists of irradiated human LNCaP prostate cancer cells that have been genetically modified. The vaccine is designed to stimulate the patient's immune system to recognize and attack prostate cancer cells, functioning as an active immunotherapy by triggering T-cell responses against tumor antigens. Developed by Vakzine Projekt Management (VPM), this approach aims to provide a novel immunotherapeutic option for patients with advanced or recurrent prostate cancer[1][3].

Beyond the preview

Go deeper on VPM4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VPM4001.

Explore the full profile